Overman et al. performed a randomized phase II clinical trial to investigate the effect of BTK inhibition in patients with advanced pancreatic cancer using acalabrutinib, an inhibitor of BTK, alone and in combination with the anti-PD-1 antibody pembrolizumab. Here, BTK is linked to pancreatic neoplasm.